A single centre randomised clinical trial to assess the antibody response to a 23-valent pneumococcal polysaccharide vaccine administered to adults aged between 50-70 years following a 0, 1 or 2 dose priming immunisation with a 7-valent pneumococcal conjugate vaccine.
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2013
At a glance
- Drugs Pneumococcal 7-valent CRM197 vaccine conjugate; Pneumococcal vaccine conjugate PPV 23
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- 03 Nov 2006 New trial record.